Dave Fornell, DAIC Editor

Dave Fornell, Editor DAIC

Blog | Dave Fornell, DAIC Editor | January 30, 2017

DAIC’s Website Broke 1 Million Pageviews; Two Key TCT Takeaways

DAIC has worked hard to bring useful technology news and resources to our readers. While we conduct reader surveys and speak to readers at site visits and conferences, one of the clearest views we have of reader interests is based on what they are reading on our website, e-newsletters and digital editions. We have responded to these analytics in what we publish and how we cover new cardiovascular technology. The result has been a big increase in our online readership over the past year. For the first time, DAIC’s website broke 1 million pageviews in November 2016. We wanted to thank our readers for helping us reach this milestone. 

See a list of the “Most Popular Cardiology Articles of 2016 From DAIC.”

See the list of “Top Cardiology Videos on DAIC in 2016.”

 

Two Key Takeaways at TCT 2016

After decompressing from the interventional information overload at the annual Transcatheter Cardiovascular Therapeutics (TCT) conference in November, I felt there were two big technology takeaways requiring an in-depth review.  These included the EXCEL Trial and the results of three studies that compared bioresorbable polymer metallic drug-eluting stents (DES) to the current standard durable polymer metallic DES. 

The EXCEL Trial was the biggest news at TCT.16. It compared the use of the Abbott Xience V DES to coronary artery bypass graft (CABG) surgery in patients with left main disease. The result of this large randomized trial was that both have equal outcomes. You can read the article with more detail at  "Stents Have Equal Outcomes to Bypass Surgery in EXCEL Trial."

Durable drug-carrier polymers on DES have been implicated as the cause of late-stent thrombosis, which has led to long-duration use of dual antiplatelet therapy (DAPT). The introduction of bioresorbable polymers was expected to eliminate late events and the need for long-term DAPT. However, results from three trials of bioresorbable polymer DES showed equal outcomes and no apparent benefit. Read more detail and here Boston Scientific's response to the data in the article "Bioresorbable Polymers on Metallic Stents Show No Superiority to Durable Polymer Stents."

 

New DAIC Editorial Board Members

DAIC recently added two new Editorial Board members who are experts in cutting-edge interventional and structural heart technologies. The first is Azeem Latib, M.D., an interventional cardiologist at Università Vita-Salute San Raffaele Milano, Milan, Italy. He is a regular speaker at  TCT and other conferences. His research interests include new transcatheter heart valve repair and replacement technologies and bioresorbable stents. Read his recent article on the Cardioband annuloplasty device, "Transcatheter Annuloplasty For Repair Versus Replacement in Functional Mitral Regurgitation."

Our second new board member is Torsten Vahl, M.D., director of experimental and translational research and assistant professor of medicine at Columbia University Medical Center, The Center for Interventional Vascular Therapy. He also is a regular speaker at TCT and is involved in bleeding-edge research and trials for new structural heart interventions. Watch a video interview with Vahl at TCT 2016, "Transcatheter Valve Technology Advancements at TCT 2016."
 

Related Content

The Foldax Tria surgical valve reimagines the heart valve by incorporating a new, proprietary biopolymer, what the vendor calls LifePolymer, with an innovative valve design intended to eliminate calcification, withstand stresses and strains without failure, and restore patient quality of life without lifelong use of anticoagulants. Tria is also the first heart valve to be robotically manufactured, reducing variability, enabling high precision, repeatability and better quality control.
News | Heart Valve Technology | June 23, 2020
June 23, 2020 – Heart valve start-up Foldax is looking to reinventi
SMT Enters Structural Heart Market With Acquisition of Vascular Concepts. The company's Hydra TAVR (TAVI) valve gained European CE mark clearance in June 2020.
News | Heart Valve Technology | June 19, 2020
June 19, 2020 — SMT (Sahajanand Medical Technologies Pvt.
SMT (Sahajanand Medical Technology Private Ltd.), a leading medical device company of India focused on cardiology, announced it Hydra transcatheter aortic valve replacement (TAVR) device received European CE mark approval. It is indicated for the treatment of patients diagnosed with aortic stenosis. #SMT #HYDRA #TAVR

The self-expanding SMT Hydra transcatheter aortic valve replacement (TAVR) device.

Feature | Heart Valve Technology | June 09, 2020
June 9, 2020 — SMT (Sahajanand Medical Technology Private Ltd.), a leading medical device company in India focused on
News | Heart Valve Technology | June 08, 2020
June 8, 2020 — Edwards Lifesciences Corp.
Edwards Lifesciences Pascal Tricuspid Valve Transcatheter Repair System Approved in Europe
News | Heart Valve Technology | May 18, 2020
May 18, 2020 — The Edwards Lifesciences Corp.
Key TAVR Takeaways From ACC 2020
Feature | Heart Valve Technology | April 20, 2020 | Dave Fornell, Editor
Some U.S.
Abbott announced its TriClip Transcatheter Tricuspid Valve Repair (TTVR) System has received European CE mark clearance as a non-surgical treatment for people with a tricuspid valve regurgitation (TR). 
Feature | Heart Valve Technology | April 09, 2020
April 9, 2020 — Abbott announced its TriClip Transcatheter Tricuspid Valve Repair (TTVR) System has received European
The Edwards Lifesciences Cardioband for tricuspid valve regurgitation. #COVID19 #coronavirus

The Edwards Lifesciences Cardioband for tricuspid valve regurgitation is one of the device trials being paused for the duration of the COVID-19 outbreak.

News | Heart Valve Technology | March 30, 2020
March 30, 2020 — Edwards Lifesciences Corp.
Conclusions from the TAVR vs surgery trial for aortic valve replacement in the U.K. presented by William D. Toff, M.D. at ACC 20. #ACC20 #ACC2020 #TAVR #TAVR

Conclusions from the real world TAVR vs. surgery trial for aortic valve replacement outcomes in the U.K., presented by William D. Toff, M.D. at ACC 20. 

News | Heart Valve Technology | March 30, 2020
March 30, 2020 — Patients in the United Kingdom (U.K.) who underwent transcatheter aortic valve replacement (TAVR) di